Drug intelligence / Profile preview

LMG324

Development stage: Discontinued
Lead developer: Alcon
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

LMG324 is a long-acting monoclonal antibody that acts as an inhibitor of vascular endothelial growth factor A (VEGF-A). It was developed by Alcon for the treatment of neovascular (wet) age-related macular degeneration (AMD). The drug was designed to be administered via intravitreal injection and aimed to reduce abnormal blood vessel growth and leakage in the retina by blocking VEGF-A activity. Clinical development reached phase 1/2 trials but was discontinued before approval[2][3][4][5].

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on LMG324.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LMG324.

Explore the full profile